🌹 Topical Rosacea Therapy Simulator

Metronidazole — Direct Anti-inflammatory Action in Rosacea

Reduces oxidative and inflammatory follicular damage.

• ROS scavenger: Mechanism (Short placeholder note)
• 0.75–1%: Typical dose (Topical gel/cream)
• ~3–4 wk: Onset (Short placeholder note)
• Mild: Demodex effect (Short placeholder note)

Neutrophil and ROS suppression

Short placeholder sentence describing this mechanism step.

Clinical response pattern

Short placeholder sentence describing typical response.

Short placeholder key-insight sentence.

Azelaic Acid — Antimicrobial and Anti-inflammatory Dual Action

Targets keratinocytes and inflammatory cytokine pathways.

• KLK5/cathelicidin: Mechanism (Short placeholder note)
• 15–20%: Typical dose (Topical gel/foam)
• ~4 wk: Onset (Short placeholder note)
• Mild-moderate: Demodex effect (Short placeholder note)

Keratinocyte normalization

Short placeholder sentence describing this mechanism step.

Cytokine pathway modulation

Short placeholder sentence describing pathway effect.

Short placeholder key-insight sentence.

Ivermectin — Anti-parasitic Clearance of Demodex Mites

Paralyzes mites via glutamate-gated chloride channels.

• GluCl agonist: Mechanism (Short placeholder note)
• 1% cream: Typical dose (Once daily)
• ~2–4 wk: Onset (Short placeholder note)
• Strong: Demodex effect (Short placeholder note)

Mite paralysis and death

Short placeholder sentence describing this mechanism step.

Secondary anti-inflammatory gain

Short placeholder sentence describing indirect benefit.

Short placeholder key-insight sentence.

Demodex Mite Density Returns Toward Normal Skin Levels

Weekly mite counts decline with sustained topical therapy.

• ~6/cm²: Baseline density (Rosacea skin average)
• <1/cm²: Normal skin (Reference threshold)
• 8–12 wk: Time to normalize (Short placeholder note)
• Ivermectin: Best agent (Short placeholder note)

Density decline kinetics

Short placeholder sentence describing decline curve.

Agent comparison

Short placeholder sentence comparing the three drugs.

Short placeholder key-insight sentence.

Inflammatory Papule and Pustule Clearance Over Treatment Course

Papule and pustule counts fall as inflammation and mites resolve.

• ~14: Baseline lesions (Short placeholder note)
• ~70–90%: Clear at 12 wk (Short placeholder note)
• Moderate: Relapse risk (Short placeholder note)
• Recommended: Maintenance (Short placeholder note)

Lesion count trajectory

Short placeholder sentence describing lesion clearance.

Long-term maintenance

Short placeholder sentence about maintaining response.

Short placeholder key-insight sentence.